bisoprolol and Apoplexy studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Research Excerpts

Excerpt	Relevance	Reference
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats."	7.79	Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013)
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol."	7.79	Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013)
"The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol."	5.24	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. ( Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN, 2017)
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats."	3.79	Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013)
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol."	3.79	Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013)
"Left ventricular hypertrophy was diagnosed using the Sokolow-Lyon indices."	1.48	Left ventricular hypertrophy diagnosed after a stroke: a case report. ( Kanyal, R; Umeojiako, WI, 2018)

Research

Studies (13)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Ambulatory Heart-rate.

B-type Natriuretic Peptide (BNP) at 6 Months.

Cardiovascular Events

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	11 (84.62)	24.3611
2020's	1 (7.69)	2.80

Authors	Studies
Iwano, T	1
Toda, H	1
Nakamura, K	1
Shimizu, K	1
Ejiri, K	1
Naito, Y	1
Mori, H	1
Masuda, T	1
Miyoshi, T	1
Yoshida, M	1
Hikasa, Y	1
Morimatsu, H	1
Ito, H	1
Kotecha, D	1
Calvert, M	1
Deeks, JJ	1
Griffith, M	1
Kirchhof, P	1
Lip, GY	1
Mehta, S	1
Slinn, G	1
Stanbury, M	1
Steeds, RP	1
Townend, JN	1
DiFrancesco, JC	1
Umeojiako, WI	1
Kanyal, R	1
Gui, H	1
Guo, YF	1
Liu, X	1
Zhang, JM	1
Yang, YL	1
Huang, GZ	1
Liu, JG	1
Bradley, A	1
Sheridan, P	1
Ashes, C	2
Judelman, S	2
Wijeysundera, DN	1
Tait, G	2
Mazer, CD	2
Hare, GM	2
Beattie, WS	2
Eisenach, JC	1
Wicker, JF	1
Bronheim, D	1
Wijeysundera, D	1
Lu, HT	1
Nordin, R	1
Othman, N	1
Choy, CN	1
Kam, JY	1
Leo, BC	1
Ramsamy, G	1
Goh, TH	1
van Lier, F	1
Schouten, O	1
Hoeks, SE	1
van de Ven, L	1
Stolker, RJ	1
Bax, JJ	1
Poldermans, D	1
Leizorovicz, A	1
Lechat, P	1
Cucherat, M	1
Bugnard, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy[NCT02391337]	Phase 4	161 participants (Actual)	Interventional	2016-12-20	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	bpm (Mean)
Beta-blocker	73.7
Digoxin	78.9

Intervention	ng/L (Median)
Beta-blocker	1209
Digoxin	1057.5

Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months

Composite Functional Status Measures- 6 Minute Walking Distance at 12 Months.

Intervention	Participants (Count of Participants)
Beta-blocker	12
Digoxin	2

Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months

Diastolic Function- Measured by the E/e'.

Intervention	metres (Median)
Beta-blocker	329
Digoxin	366

"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months

Drug Discontinuation Rate Within 12 Months.

Intervention	Ratio of E/e' (Mean)
Beta-blocker	10.8
Digoxin	10.8

Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months

Hospital Admission Rate

Left Ventricular Ejection Fraction

Intervention	Participants (Count of Participants)
Beta-blocker	9
Digoxin	2

Intervention	Participants (Count of Participants)
Beta-blocker	19
Digoxin	11

The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months

Number of Participants With Unplanned Hospital Admissions.

Intervention	percentage of ejection fraction (Mean)
Beta-blocker	59.8
Digoxin	59.7

Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.

Patient Reported Outcomes (EQ-5D-5L)

Intervention	Participants (Count of Participants)
Beta-blocker	19
Digoxin	11

"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months

Patient Reported Outcomes- (AFEQT) at 12 Months.

Intervention	units on a scale (Mean)
Beta-blocker	0.62
Digoxin	0.66

As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months

Patient Reported Quality of Life (SF-36)

Intervention	score on a scale (Mean)
Beta-blocker	68.1
Digoxin	75.6

"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.

Patient Reported Outcomes (SF36) Version 2 at 12 Months.

Intervention	score on a scale (Mean)
Beta-blocker	29.7
Digoxin	31.9

As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months

Intervention	score on a scale (Mean)
	Physical Component Summary	Mental Component Summary	Physical Function Domain Score	Role Limitation Due to Physical Domain score	Role Limitation Due to Emotional Problems Domain score	Social Functioning Domain Score	Mental Health Domain	Energy/Vitality Domain Score	Pain Score	General Health Perception Domain Score
Beta-blocker	29.4	51.3	27.5	32	40.7	43.3	51.8	42	41.9	39.6
Digoxin	32.5	53.6	31.5	37	45.2	45.6	51.3	47.1	40.5	42.8

Article	Year
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study. Journal of cardiology, 2021, Volume: 78, Issue:5 Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr	2021
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ open, 2017, Jul-20, Volume: 7, Issue:7 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolo	2017
Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery. The American journal of cardiology, 2010, Jan-01, Volume: 105, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Dose-Response Relationship, Drug; Female; Humans; Inc	2010

Article	Year
Artery of Percheron ischaemic stroke revealed by brain MRI DWI/ADC sequences. BMJ case reports, 2017, Dec-02, Volume: 2017 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Brain Ischemia; Cerebral Arteries; Diffusi	2017
Left ventricular hypertrophy diagnosed after a stroke: a case report. Journal of medical case reports, 2018, Mar-22, Volume: 12, Issue:1 Topics: Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Cardiomyopathy, Hypertrophic; Chest Pain; Co	2018
Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. CNS neuroscience & therapeutics, 2013, Volume: 19, Issue:3 Topics: Animals; Antihypertensive Agents; Baroreflex; Bisoprolol; Drug Therapy, Combination; Heart Rate; Mal	2013
Atrial fibrillation. BMJ (Clinical research ed.), 2013, Jun-17, Volume: 346 Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli	2013
Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology, 2013, Volume: 119, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Cohort Studies; Female; Humans;	2013
Patient safety: anesthesiology contributions and supplements to the American Society of Anesthesiologists' Annual Meeting. Anesthesiology, 2013, Volume: 119, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post	2013
Does β selectivity really affect outcome? Anesthesiology, 2014, Volume: 120, Issue:5 Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post	2014
In reply. Anesthesiology, 2014, Volume: 120, Issue:5 Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post	2014
Biatrial thrombi resembling myxoma regressed after prolonged anticoagulation in a patient with mitral stenosis: a case report. Journal of medical case reports, 2016, Aug-10, Volume: 10, Issue:1 Topics: Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Directive Counsel	2016

bisoprolol and Apoplexy